MPP invites Expressions of Interest (EoI) from potential sublicensees based anywhere in the world for sublicences to manufacture and sell ensitrelvir in the licensed territory:
More information about the EoI process
Deadline for applying: 26 November 2022, 11.59pm CET
About ensitrelvir fumaric acid (S-217622)
About the Medicines Patent Pool
About Shionogi
Shionogi & Co., Ltd. is a leading global research-driven pharmaceutical company based in Japan dedicated to bringing benefits to patients based on its corporate philosophy of “supplying the best possible medicine to protect the health and wellbeing of the patients we serve.” The company has discovered and developed novel medicines for HIV, influenza and antimicrobial resistance and currently markets products in several therapeutic areas including anti-infectives with the first siderophore cephalosporin. Other therapeutic areas, and the focus of the company’s pipeline, include CNS/psychoneurological diseases, oncology and pain. For more information on Shionogi & Co., Ltd., visit https://www.shionogi.com/global/en/.
Shionogi Inc. is the U.S. subsidiary of Shionogi & Co., Ltd. based in New Jersey. For more information on Shionogi Inc., please visit https://www.shionogi.com/us/en/.
Shionogi B.V. is the European headquarters of Shionogi & Co., Ltd. For more information on Shionogi B.V., please visit https://www.shionogi.com/eu/en/ .
Other partners
Ping An
Shionogi Media Contact:
MPP Media Contact
press@medicinespatentpool.org (Geneva, Switzerland)
PSingh@burness.com (Washington, D.C., USA)